What factors do you consider when deciding on adjuvant therapy for a resected stage IIIB melanoma patient?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How would a low tumor mutational burden (<10) influence your decision to offer neoadjuvant immunotherapy for cutaneous squamous cell carcinoma?

For a patient with metastatic melanoma with small, asymptomatic brain mets what is your preferred systemic therapy?

In a patient with unresectable, multifocal recurrent cutaneous squamous cell carcinoma and underlying T-cell large granular lymphocytic leukemia with baseline moderate pancytopenia, is anti-PD-1 therapy (e.g., cemiplimab) an appropriate and safe treatment option?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.